Co-founder & CEO from formulating concept of Post-evolutionary Biologics to VC fundingStrategy, business development, & fund raising

• Executive Committee• Accountable for a robust pipeline of immuno-oncology therapeutics derived from de novo cytokine mimetics• Leadership of a cross-functional team encompassing machine learning-based de novo protein design, protein sciences, immunology, cancer biology, and translational sciences

• Responsible for a pipeline of innovative antibody-drug conjugates (ADCs) from target discovery through IND submission and early clinical development• Led an integrated, multi-disciplinary team with expertise in target discovery and validation, cancer and cell biology, high-throughput screening (HTS) and automation, bioinformatics/computational biology, experimental genomics and proteomics, histology and in situ spatial biology, and in vivo pharmacology• Head of cross-functional program teams in preclinical, translational, and early clinical stages of pipeline• Established strategy and direction as part of Research Leadership Team, Research-Corporate Development Team, and Research-Intellectual Property Team

Provide guidance on translational and early clinical development of combinations for cancer treatment.

• Led a team of cell biologists with expertise in high-throughput experimentation• Discovered predictive and pharmacodynamic biomarkers for investigational oncology therapeutics• Identified synergistic drug combinations using ultra-HTS technologies• Identified novel drug targets through integration of genome-scale RNAi screening and molecular profiling

• Discovered novel drug targets and identified predictive biomarkers for investigation oncology drugs by integrating functional genomics and small molecule HTS with multiple genomic profiling platforms.• Rosetta Inpharmatics is a wholly owned subsidiary of Merck and Co., Inc.

Elucidated molecular mechanisms of signal transduction cross-talk between the Ras and Rho families of small GTPases